regulatory
confidence high
sentiment positive
materiality 0.60
FDA clears IND for Compass Therapeutics' CTX-009 Phase 2 study in biliary tract cancers
Compass Therapeutics, Inc.
- FDA cleared IND for CTX-009 bispecific antibody targeting DLL4 and VEGF-A.
- Enables global Phase 2 trial in advanced biliary tract cancers including cholangiocarcinoma.
- Will expand ongoing South Korean Phase 2; US clinical sites expected to open in Q2 2022.
- CEO Thomas Schuetz noted CTX-009 has potential as important new therapy for BTC patients.